Lantern Pharma's LP-184 Gets Orphan Drug Designation In Treatment Of Pancreatic Cancer

(RTTNews) - Clinical stage biopharmaceutical company Lantern Pharma (LTRN) said the FDA has granted Orphan Drug Designation for LP-184 in the treatment of pancreatic cancer. LP-184 is a next-generation DNA-damaging agent being developed for pancreatic cancer in a collaboration with Fox Chase Cancer Center.

LP-184, or hydroxyureamethylacylfulvene, is a small molecule drug candidate which is a next generation alkylating agent that preferentially damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds.

Last month, Lantern Pharma reported that preclinical data has demonstrated that LP-184 showed significant and rapid pancreatic tumor shrinkage, by over 90%, in in-vivo mouse models in 8 weeks.

Shares of Lantern Pharma were up nearly 12% in pre-market trade on Wednesday.